Document is current

Article History

Received: 5 May 2025

Accepted: 20 August 2025

First Online: 24 October 2025

Declarations

:

: I.D., R.M., S.B., P.A.U.T., S.S. and T.K. received honoraria from GSK for serving in the steering committee of this project, but did not receive any fee for writing the manuscript. I.D. has received research grants from Baxter, Sanofi, and Medtronic; has been on advisory boards of GSK, Sanofi, AstraZeneca, and Vifor; and has received honoraria from GSK, Sanofi, AstraZeneca, and Vifor for consultation and speaker meetings. R.M. has been a member of advisory boards for Amgen, Astellas, and GSK; has received consulting fees from Bayer and GSK; and has been an invited speaker at meetings supported by Amgen, Astellas, Bayer, Vifor, and AstraZeneca. T.K. has been a member of advisory boards for AstraZeneca, Vifor, and GSK; has received consulting fees from Bayer, Hexal, Vifor, and GSK; and has been an invited speaker at meetings supported by GSK. P.A.U.T. declares receipt of advisory and/or lecture fees from Astellas, AstraZeneca, GSK, Hemotech, Sanofi, Théradial, and Vifor. S.B. has received consultancy fees from GSK, AstraZeneca, and Bayer. S.S. has received consultancy fees from Astellas, Biotest, Takeda, Medice, and GSK. N.H. and V.E. are employees and shareholders of GSK. R.P., M.S., L.V.M., and J.P. are employees of Adelphi Values PROVE™; Adelphi Values PROVE™ received funding from GSK to conduct the Delphi study through to manuscript development.

: As the study did not involve human participants, no ethical approval was required.

: Healthcare professionals/panellists consented to anonymous publication of their statements and of the results of the study.